
The Changes of HIF-1α and ICAM-1 Expression after Miana (Coleus Scutellariodes [L]) Treatment in Balb/C Mice with Mycobacterium Tuberculosis Infection
Author(s) -
Rosamarlina Rosamarlina,
Mochammad Hatta,
Irawaty Djaharuddin,
Ilhamjaya Patellongi,
Agus Dwi Susanto,
Andi Asadul Islam,
Muhammad Nasrum Massi,
Agussalim Bukhari,
Maurizio Massi,
Agussalim Bukhari,
Arif Santoso,
Arif Santoso,
Ade Rifka Junita,
Ressy Dwiyanti,
Sesilia Rante Pakadang
Publication year - 2022
Publication title -
biomedical and pharmacology journal/biomedical and pharmacology journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.191
H-Index - 18
eISSN - 2456-2610
pISSN - 0974-6242
DOI - 10.13005/bpj/2344
Subject(s) - medicine , placebo , icam 1 , rifampicin , mycobacterium tuberculosis , tuberculosis , pharmacology , inflammation , immunology , traditional medicine , pathology , cell adhesion molecule , alternative medicine
Background: Increasing resistance to TB drugs raises the challenge of TB eradication. Miana leaves is Indonesian traditional herbal medicine, have antimicrobial, anti-inflammatory, and immunoregulatory action. Not much is known about the effect of Miana on HIF-1α and ICAM-1, the immunoregulators of infection and inflammation. This study aims to elucidate the effect of Miana on HIF-1α and ICAM-1 in M. tuberculosis (Mtb) infected mice. Materials and Methods: This experimental study used Mtb infected Balb/c mice were divided into 4 groups; group 1 is placebo, group 2 is treated with Rifampicin as Anti TB drug, group 3 is treated with Miana, and group 4 is treated with Miana + Anti TB drug. HIF-1α and ICAM-1 serum levels were analyzed using ELISA. Results: There is a significant difference of mean HIF-1α (p= 0.00, F = 114.21) and ICAM-1 (p= 0.00, F = 113.11) between the four groups after treatment. HIF-1α level is significantly lower in anti TB treatment, Miana, and Miana + anti TB treatment compared to placebo (mean difference (MD) 35,764.67, p=0.00; 29,230.98, p=0.000; 38,489.62, p=0.00, respectively). Furthermore, ICAM-1 level is significantly lower in anti TB treatment, Miana, and Miana + anti TB treatment compared to placebo (MD 95,449.68, p=0.00; 79,509.69, p=0.00; 108,672.83, p=0.00, respectively). Conclusion: HIF-1α and ICAM-1 expression was reduced after Miana administration. Miana can be a potential complement to anti-TB treatment but cannot replace rifampicin as anti-TB drugs.